AI x Bio Pitch Contest — Hegemon Bio

Hegemon Bio co-founder Nathan Skene argues that better target selection for complex genetic traits requires evidence about the cells and DNA-binding events linked to disease. He discusses the gaps in available training data and methods his research team has developed to gather more relevant measurements. The judges ask about cell types, initial indications, data requirements, and brain diseases.